Head-to-head · WeighScore
Garcia Weight Loss, Aesthetics & Hormone Therapy vs Injectco
By GLP-1 ScorecardUpdated
Score comparison
Injectco has the higher recorded score — 64.6/100 to 59.4/100.
Injectco grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Injectco is a Dallas-based medspa offering compounded GLP-1 prescriptions shipped from licensed US partner pharmacies.
Before you choose
Before comparing the headline prices, the Garcia Weight Loss, Aesthetics & Hormone Therapy review and the Injectco review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Garcia Weight Loss, Aesthetics & Hormone Therapy vs Mojoon and HealthRX vs Injectco compare each of them with another graded program, and the list of alternatives to Garcia Weight Loss, Aesthetics & Hormone Therapy ranks the programs closest to Garcia Weight Loss, Aesthetics & Hormone Therapy on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Live Vital review covers one graded close to these two, at 62.7/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Garcia Weight Loss, Aesthetics & Hormone Therapy | Injectco |
|---|---|---|
| WeighScore | 59.4/100 | 64.6/100 |
| Grade | C | C |
| Site position | #374 | #253 |
| Semaglutide | $400/mo (starting dose, compounded) | $425/mo (compounded; consult, labs and delivery included) |
| Tirzepatide | Not disclosed | $425/mo (starting dose, compounded) |
| Coverage | 1 state | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Established since 2000 with 4 Tampa Bay locations and 50,000+ patients treated
- GLP-1 program includes full metabolic and hormone lab panel
- Medication and supplies shipped directly to your door from partner pharmacy
- Free 15-minute consultation; both weekly-visit (Premier) and monthly-visit (Standard) tiers
- LegitScript transparency certification listed in footer
What to consider
- Florida only — 4 locations in Tampa Bay metro area only
- Pricing not publicly listed on website ($400/month per Facebook ad)
- Specific GLP-1 drug (semaglutide vs tirzepatide) not disclosed on site
- Telemedicine availability not confirmed on site despite Facebook ad claims
- In-person visit model less convenient than fully online telehealth providers
Strengths
- Physical address in Dallas TX
- Founded July 2021 — established
- Published monthly price of $425 for compounded semaglutide or tirzepatide, with consult, labs and delivery included
What to consider
- LegitScript or PCAB accreditation has not been independently verified
- Primarily a medspa (Botox, fillers, hair restoration)
- May be Texas-only — unclear if telehealth ships nationally
- No named pharmacy partners
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.